Breast Cancer Grading: Histopathological vs. Genomic
Author Information
Author(s): Nilotpal Chowdhury
Primary Institution: Aarupadai Veedu Medical College
Hypothesis
Does histopathological grading retain its prognostic impact when adjusted for genomic grading in breast cancer?
Conclusion
Histopathological grade remains a significant prognostic factor in low genomic grade tumors, while genomic grade can stratify histopathological grade tumors into distinct prognostic groups.
Supporting Evidence
- Histopathological grade was a significant predictor for survival in low genomic grade patients.
- Genomic grade can stratify histopathological grade tumors into distinct prognostic groups.
- The prognostic effects of both histopathological and genomic grades are time-varying.
Takeaway
This study looks at how two ways of grading breast cancer can help doctors understand how serious the cancer is. One method is based on looking at the cancer under a microscope, and the other is based on gene information.
Methodology
Four publicly available gene expression datasets were analyzed using Kaplan-Meier curves, log rank test, and Cox regression to study recurrence-free survival and distant metastasis-free survival.
Potential Biases
Interobserver variability in histopathological grading may affect the results.
Limitations
The study faced challenges due to missing data and potential bias from the datasets used.
Participant Demographics
The study included 286 node-negative breast cancer patients who did not receive adjuvant therapy.
Statistical Information
P-Value
0.003 for DMFS, p<0.001 for RFS
Confidence Interval
95% CI provided in tables
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website